Letter
Medicine, General & Internal
Elif Hindie
Summary: The study found that treatment with teclistamab resulted in a high overall response rate of 63.0% and a median progression-free survival of 11.3 months in patients with relapsed or refractory myeloma. Additionally, the change in serum levels of soluble BCMA correlated with treatment response.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Philippe Moreau, Alfred L. Garfall, Niels W. C. J. van de Donk, Hareth Nahi, Jesus F. San-Miguel, Albert Oriol, Ajay K. Nooka, Thomas Martin, Laura Rosinol, Ajai Chari, Lionel Karlin, Lotfi Benboubker, Maria-Victoria Mateos, Nizar Bahlis, Rakesh Popat, Britta Besemer, Joaquin Martinez-Lopez, Surbhi Sidana, Michel Delforge, Lixia Pei, Danielle Trancucci, Raluca Verona, Suzette Girgis, Shun X. W. Lin, Yunsi Olyslager, Mindy Jaffe, Clarissa Uhlar, Tara Stephenson, Rian Van Rampelbergh, Arnob Banerjee, Jenna D. Goldberg, Rachel Kobos, Amrita Krishnan, Saad Z. Usmani
Summary: Teclistamab demonstrated promising efficacy in patients with relapsed or refractory multiple myeloma, leading to high rates of deep and durable response. Common adverse events included cytokine release syndrome, cytopenias, and infections, with toxic effects mostly grade 1 or 2.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, Arnob Banerjee, Tara Stephenson, Xuewen Ma, Shoba Shetty, Tong-Yuan Yang, Brandi W. Hilder, Qun Jiao, Brett Hanna, Homer Adams, Yu-Nien Sun, Amarnath Sharma, Jennifer Smit, Jeffrey R. Infante, Jenna D. Goldberg, Yusri Elsayed
Summary: This study used pharmacokinetic modeling and ex vivo cytotoxicity estimates to determine the therapeutic range of Teclistamab, a bispecific antibody. The recommended Phase II dose was identified, and patients who responded to this dose showed exposure above the maximum effective concentration in both serum and bone marrow.
Review
Immunology
Leora S. Boussi, Zachary M. Avigan, Jacalyn Rosenblatt
Summary: Despite advances in treatment for multiple myeloma, understanding the mechanisms of immune evasion and resistance to therapy is critical for developing more effective treatments. Cellular adoptive therapy, particularly CAR T cell therapy, has shown promising results in refractory cases and may be a viable option for treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Darren Pan, Joshua Richter
Summary: Teclistamab is the first approved BCMAxCD3 bispecific antibody for treating relapsed or refractory multiple myeloma. It has shown impressive efficacy in heavily pretreated patients and is more accessible compared to BCMA-directed CAR T cells. However, it does come with notable adverse effects such as CRS, infections, and neurotoxicity, which require specific precautions and prophylactic measures.
CANCER MANAGEMENT AND RESEARCH
(2023)
Article
Oncology
Doris K. Hansen, Surbhi Sidana, Lauren C. Peres, Christelle Colin Leitzinger, Leyla Shune, Alexandria Shrewsbury, Rebecca Gonzalez, Douglas W. Sborov, Charlotte Wagner, Danai Dima, Hamza Hashmi, Mehmet H. Kocoglu, Shebli Atrash, Gary Simmons, Nilesh Kalariya, Christopher Ferreri, Aimaz Afrough, Ankit Kansagra, Peter Voorhees, Rachid Baz, Jack Khouri, Melissa Alsina, Joseph McGuirk, Frederick L. Locke, Krina K. Patel
Summary: A retrospective analysis showed that the safety and efficacy of standard-of-care ide-cel therapy in RRMM patients were similar to those seen in the phase II KarMMa trial, despite most patients not meeting the trial eligibility criteria.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Peter Neumeister, Eduard Schulz, Katrin Pansy, Marta Szmyra, Alexander Ja Deutsch
Summary: Multiple myeloma (MM) is a malignant and incurable disease characterized by the interaction between tumor cells and the bone marrow microenvironment. Therapeutic interventions targeting the bone marrow microenvironment have become a novel strategy for treating multiple myeloma.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Health Care Sciences & Services
Alessandro Gozzetti, Monica Bocchia
Summary: The survival rate of multiple myeloma has increased in the past 20 years due to new treatments, improved clinical management, and a better understanding of the disease. Novel drugs and therapeutic strategies have allowed a considerable number of patients to achieve durable remission or even disease disappearance.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Review
Oncology
Danai Dima, Dongxu Jiang, Divya Jyoti Singh, Metis Hasipek, Haikoo S. Shah, Fauzia Ullah, Jack Khouri, Jaroslaw P. Maciejewski, Babal K. Jha
Summary: Multiple myeloma (MM) is a complex hematologic malignancy that remains incurable despite several therapeutic advancements. This review discusses the current treatment paradigm of MM and highlights promising future approaches.
Article
Oncology
Xin Miao, Liviawati S. Wu, Shun Xin Wang Lin, Yan Xu, Yang Chen, Yuki Iwaki, Rachel Kobos, Tara Stephenson, Kristy Kemmerer, Clarissa M. Uhlar, Arnob Banerjee, Jenna D. Goldberg, Danielle Trancucci, Amit Apte, Raluca Verona, Lixia Pei, Rachit Desai, Kathleen Hickey, Yaming Su, Daniele Ouellet, Mahesh N. Samtani, Yue Guo, Alfred L. Garfall, Amrita Krishnan, Saad Z. Usmani, Honghui Zhou, Suzette Girgis
Summary: This study reports the population pharmacokinetics and exposure-response relationships of teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma. The efficacy and safety of teclistamab were evaluated in the MajesTEC-1 study.
Article
Oncology
Ajay K. Nooka, Cesar Rodriguez, Maria Victoria Mateos, Salomon Manier, Katherine Chastain, Arnob Banerjee, Rachel Kobos, Keqin Qi, Raluca Verona, Margaret Doyle, Thomas G. Martin, Niels W. C. J. van de Donk
Summary: Infections were examined in patients with relapsed/refractory multiple myeloma treated with teclistamab, and the study found that they were at increased risk of infection. Various types of infections were reported, including COVID-19 and respiratory infections. Prompt intervention and appropriate screening, prophylaxis, and management of infections are important for these patients.
Review
Medicine, General & Internal
Niels W. C. J. van de Donk, Charlotte Pawlyn, Kwee L. Yong
Summary: Multiple myeloma is the second most common haematological malignancy in high-income countries. Current treatment strategies have extended patient survival, but the majority will ultimately die from the disease. Diagnostics and risk stratification are crucial for prognosis and treatment strategies.
Review
Oncology
Craig T. Wallington-Beddoe, Rachel L. Mynott
Summary: New approaches are needed to stratify multiple myeloma patients based on prognosis and therapeutic decision-making, however, insufficient information currently exists to utilize biomarkers to tweak treatment. With the increasing complexity of drug classes used to treat multiple myeloma, clinically useful biomarkers are crucial in guiding personalized patient management.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Article
Biochemical Research Methods
Ziyang Ma, Jeongyoun Ahn
Summary: The study proposed a new method that can reveal the ordinal structure of classes in high-dimensional data and applied it to predict the response of multiple myeloma patients to different drugs. Comparative analysis with existing methods showed that the proposed method achieves competitive predictive performance while maintaining the intrinsic ordinal structure of classes.
Article
Hematology
Mohamad Mohty, Herve Avet-Loiseau, Jean-Luc Harousseau
Summary: With recent therapeutic advancements, operational cure for multiple myeloma is becoming a realistic goal. The correlation between MRD negativity and improved patient outcomes suggests MRD as a surrogate for potential long-term cure. Various parameters influence the value and impact of MRD, with different treatment approaches leading to potential operational cure in both younger and older patients.
Article
Hematology
Fortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Paolo Sportoletti, Luca Laurenti, Marta Coscia, Yair Herishanu, Sabrina Bossio, Marzia Varettoni, Roberta Murru, Annalisa Chiarenza, Andrea Visentin, Adalgisa Condoluci, Riccardo Moia, Daniela Pietrasanta, Giacomo Loseto, Ugo Consoli, Ilaria Scortechini, Francesca Maria Rossi, Antonella Zucchetto, Hamdi Al-Janazreh, Ernesto Vigna, Enrica Antonia Martino, Francesco Mendicino, Ramona Cassin, Graziella D'Arrigo, Sara Galimberti, Angela Rago, Ilaria Angeletti, Annalisa Biagi, Ilaria Del Giudice, Riccardo Bomben, Antonino Neri, Gilberto Fronza, Paola Monti, Paola Menichini, Giovanna Cutrona, Ozren Jaksic, Davide Rossi, Francesco Di Raimondo, Antonio Cuneo, Gianluca Gaidano, Aaron Polliack, Livio Trentin, Robin Foa, Manlio Ferrarini, Valter Gattei, Massimo Gentile
Summary: The study compared the effectiveness of IB and IDELA-R in prolonging overall survival in CLL patients, with results indicating a superior protective effect of IB over IDELA-R. Despite some limitations, these observations could provide valuable insights for clinical practice.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2021)
Article
Hematology
Fortunato Morabito, Giovanni Tripepi, Ernesto Vigna, Sabrina Bossio, Graziella D'Arrigo, Enrica Antonia Martino, Francesca Storino, Anna Grazia Recchia, Gilberto Fronza, Francesco Di Raimondo, Monica Colombo, Franco Fais, Antonino Neri, Giovanna Cutrona, Manlio Ferrarini, Massimo Gentile
Summary: The study validates the predictive value of AIPS-E and IPS-E for time to first treatment in newly diagnosed CLL patients, demonstrating their accurate prognostic utility for individual patients and potential for precise stratification of early-stage patients.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2021)
Article
Hematology
Fortunato Morabito, Elena Zamagni, Concetta Conticello, Vincenzo Pavone, Salvatore Palmieri, Sara Bringhen, Monica Galli, Silvia Mangiacavalli, Daniele Derudas, Elena Rossi, Roberto Ria, Lucio Catalano, Paola Tacchetti, Giuseppe Mele, Iolanda Donatella Vincelli, Enrica Antonia Martino, Ernesto Vigna, Cirino Botta, Antonella Bruzzese, Anna Mele, Lucia Pantani, Serena Rocchi, Bruno Garibaldi, Nicola Cascavilla, Stelvio Ballanti, Giovanni Tripepi, Ferdinando Frigeri, Antonetta Pia Falcone, Clotilde Cangialosi, Giovanni Reddiconto, Giuliana Farina, Marialucia Barone, Ilaria Rizzello, Pellegrino Musto, Valerio De Stefano, Maurizio Musso, Maria Teresa Petrucci, Massimo Offidani, Antonino Neri, Nicola Di Renzo, Francesco Di Raimondo, Mario Boccadoro, Michele Cavo, Massimo Gentile
Summary: The non-randomized comparison between KRd and EloRd therapies in relapsed/refractory multiple myeloma patients showed that KRd treatment led to a higher probability of achieving a CR+VGPR response, reduced progression or death risk, and had a greater effect on patients achieving CR+VGPR compared to those achieving < VGPR. The overall results suggest potential benefits of KRd therapy over EloRd in clinical practice.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2022)
Review
Hematology
Antonella Bruzzese, Enrica Antonia Martino, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Carlo Bova, Gianfranco Filippelli, Isabella Capodanno, Antonino Neri, Fortunato Morabito, Massimo Gentile, Ernesto Vigna
Summary: Iron overload can be caused by a congenital impairment of iron regulation, increased intestinal iron absorption, or chronic transfusions. Diagnosing iron overload is challenging, with liver biopsy being the gold standard despite its invasiveness. Noninvasive techniques have allowed for better understanding of iron overload in different organs. Serum ferritin estimation is the most commonly used diagnostic tool, although it may not be specific. Hematological conditions such as myelodysplastic syndromes, sickle cell disease, and thalassemia can cause iron overload, which can be treated with chelators like deferiprone, deferoxamine, and deferasirox.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2023)
Editorial Material
Biotechnology & Applied Microbiology
Antonella Bruzzese, Enrica Antonia Martino, Ernesto Vigna, Enrico Iaccino, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Gianfranco Filippelli, Antonino Neri, Fortunato Morabito, Massimo Gentile
EXPERT OPINION ON BIOLOGICAL THERAPY
(2023)
Article
Oncology
Rosaria De Filippi, Gianpaolo Marcacci, Enrico Derenzini, Maurizio Musso, Daniela Donnarumma, Emanuela Morelli, Caterina Patti, Alessio Maria Edoardo Maraglino, Renato Scalone, Luigia Simeone, Cristina Becchimanzi, Sara Mele, Stefania Crisci, Fortunato Morabito, Antonio Pinto
Summary: This study evaluated the effectiveness of programmed death receptor-1 (PD-1)-blockade as a consolidation treatment for high-risk patients with relapsed and refractory Hodgkin Lymphoma (HL) after autologous stem cell transplantation (ASCT). The results showed that post-ASCT consolidation with anti-PD1 is feasible and effective, and may be a valuable management option for patients at high risk of recurrence.
Review
Pharmacology & Pharmacy
Antonella Bruzzese, Caterina Labanca, Enrica Antonia Martino, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Antonino Neri, Annalisa Imovilli, Fortunato Morabito, Ernesto Vigna, Massimo Gentile
Summary: Traditional treatment strategies for AML have relied on chemotherapy, but recent developments in hypomethylating agents and small molecules have significantly changed the landscape of AML therapy. Drugs such as Venetoclax, Midostaurin, Gilteritinib, Ivosidenib, and Enasidenib have made significant advancements in AML treatment.
EXPERT OPINION ON PHARMACOTHERAPY
(2023)
Review
Oncology
Antonella Bruzzese, Enrica Antonia Martino, Caterina Labanca, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Antonino Neri, Annalisa Imovilli, Fortunato Morabito, Ernesto Vigna, Massimo Gentile
Summary: Tagraxofusp, a recombinant molecule composed of human interleukin-3 and truncated diphtheria toxin, has shown high efficacy and acceptable safety profile in patients with BPDCN. It has also been explored in other myeloid malignancies with high CD123 expression, both as monotherapy and in combination strategies. Combination therapies, such as tagraxofusp-azacytidine-venetoclax, have shown promising results. The downregulation of DPH1, which is associated with resistance to tagraxofusp, can be reversed by azacitidine.
HEMATOLOGICAL ONCOLOGY
(2023)
Article
Hematology
Antonella Bruzzese, Ernesto Vigna, Dario Terzi, Sonia Greco, Enrica Antonia Martino, Valeria Vangeli, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Rosellina Morelli, Antonino Neri, Fortunato Morabito, Francesco Zinno, Antonio Mastroianni, Massimo Gentile
Summary: COVID-19 can lead to TTP and cause coagulation disorders, but the treatment for COVID-19-associated TTP is still under debate.
HEMATOLOGY REPORTS
(2023)
Article
Biochemistry & Molecular Biology
Domenica Ronchetti, Vanessa Favasuli, Paola Monti, Giovanna Cutrona, Sonia Fabris, Ilaria Silvestris, Luca Agnelli, Monica Colombo, Paola Menichini, Serena Matis, Massimo Gentile, Ramil Nurtdinov, Roderic Guigo, Luca Baldini, Gilberto Fronza, Manlio Ferrarini, Fortunato Morabito, Antonino Neri, Elisa Taiana